public relations officers, page-11

Other than the brilliant fundumentals of the company's pipelines I truly have no idea. Hopefully there will be a cornerstone investor. The possiblity of a takeover also hangs around in my mind for there are always characters who will jump to buy wherever they see:

- a significant, growing, near term revenue stream with near certainty;
- valuable, well progressed pipelines; and
- a fire sale price.

Everyone wants to make money without spending much or taking much risk. How much risk CDY presents investors depends on how much they have to invest. I hope I eat these words but CDY may now be more of an M&A play than a biotech play.

Other views?

cheers